NCT00871741View on ClinicalTrials.gov

Feasibility Study of GlaxoSmithKline Biologicals' GSK2202083A Vaccine in Healthy Infants at 3, 5 and 11 Months of Age.

PHASE2TerminatedINTERVENTIONAL
Enrollment

16

Participants

Timeline

Start Date

April 1, 2009

Primary Completion Date

June 25, 2009

Study Completion Date

June 25, 2009

Conditions
TetanusPoliomyelitisNeisseria MeningitidisHaemophilus Influenzae Type bDiphtheriaAcellular PertussisHepatitis B
Interventions
BIOLOGICAL

GSK2202083A vaccine

Intramuscular, three doses

BIOLOGICAL

Infanrix hexa

Intramuscular, three doses

BIOLOGICAL

Menjugate

Intramuscular, two doses

Trial Locations (8)

841 08

GSK Investigational Site, Bratislava

851 05

GSK Investigational Site, Bratislava

026 01

GSK Investigational Site, Dolný Kubín

929 01

GSK Investigational Site, Dunajská Streda

940 01

GSK Investigational Site, Nové Zámky

034 01

GSK Investigational Site, Ružomberok

943 01

GSK Investigational Site, Štúrovo

917 01

GSK Investigational Site, Trnava

Sponsors

Lead Sponsor

GlaxoSmithKline
All Listed Sponsors
lead

GlaxoSmithKline

INDUSTRY